GNPX News and Press, Genprex Inc. From 04/09/24

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting PR Newswire Compelling Data Validates the Potential...

2024-04-03 08:46:01 ET More on Genprex Genprex to effect 1-for-40 reverse stock split to regain Nasdaq compliance Seeking Alpha’s Quant Rating on Genprex Historical earnings data for Genprex Financial information for Genprex Read the full art...

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer PR Newswire Multiple clinical trial sites to be opened under collaboration with large network of community-based oncol...

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced that its research collaborators have published positive preclinical data for the NPRL2 tumor suppressor gene, utilizin...

Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System PR Newswire NPRL2 Gene Therapy Induces Anti-Tumor Activity in Anti-PD1 Resistant KRAS/STK11 Mutant Non-Small Cell Lung Cancer in a Humanized Mouse Model ...

China Resources Beer (Holdings) Company Limited ADR (CRHKY) is expected to report for Q4 2023 Melco International Development Ltd. (MDEVF) is expected to report for quarter end 2023-12-31 Meridian Mining UK Societas (MRRDF) is expected to report $0 for Q4 2023 BKF Capital Group Inc (B...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has closed on its registered direct offering. The offering, which was priced in accordance with NASDAQ guidelines, iincluded the sale and issuance of...

Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire AUSTIN, Texas , March 22, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene ther...

2024-03-20 10:13:02 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Johnson & Johnson, Boston Scientific least shorted stocks in S&...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has entered into definitive agreements. The agreements are for the sale and issuance of 1,542,112 shares of common stock (or prefunded warrants in li...